Chai Zong-Tao, Zhang Xiu-Ping, Shao Min, Ao Jian-Yang, Chen Zhen-Hua, Zhang Fan, Hu Yi-Ren, Zhong Cheng-Qian, Lin Jian-Hua, Fang Kun-Peng, Wu Meng-Chao, Lau Wan Yee, Cheng Shu-Qun
Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Department of Hepatobiliary and Pancreatic Surgical Oncology, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Ann Transl Med. 2021 Feb;9(3):247. doi: 10.21037/atm-20-2229.
Hepatocellular carcinoma (HCC) commonly occurs in patients with splenomegaly. This study aimed to investigate the impact of splenomegaly with or without splenectomy on long-term survival of HCC patients with portal vein tumor thrombus (PVTT) treated with liver resection (LR).
HCC patients with PVTT who underwent LR from 2005 to 2012 from 6 hospitals were retrospectively studied. The long-term overall survival (OS) and recurrence-free survival (RFS) were compared between patients with or without splenomegaly, and between patients who did or did not undergo splenectomy for splenomegaly. Propensity score matching (PSM) analysis was performed to match patients in a 1:1 ratio.
Of 716 HCC patients with PVTT who underwent LR, 140 patients had splenomegaly (SM group) and 576 patients had no splenomegaly (non-SM group). The SM group was further subdivided into 49 patients who underwent splenectomy (SPT group), and 91 patients who did not received splenectomy (non-SPT group). PSM matched 140 patients in the SM group, and 49 patients in the SPT group. Splenomegaly was an independent risk factor of poor RFS and OS. The OS and RFS rates were significantly better for patients in the non-SM group than the SM group (OS: P<0.001; RFS: P<0.001), and for patients in the SPT group than the non-SPT group (OS: P<0.001; RFS: P<0.001).
Patients who had splenomegaly had significantly worse survival in HCC patients with PVTT. Splenectomy for splenomegaly significantly improved long-term survival in these patients.
肝细胞癌(HCC)常见于脾肿大患者。本研究旨在探讨脾肿大伴或不伴脾切除术对接受肝切除术(LR)治疗的门静脉癌栓(PVTT)HCC患者长期生存的影响。
回顾性研究2005年至2012年期间6家医院接受LR治疗的PVTT HCC患者。比较有或无脾肿大患者之间以及因脾肿大接受或未接受脾切除术患者之间的长期总生存(OS)和无复发生存(RFS)情况。进行倾向评分匹配(PSM)分析以1:1比例匹配患者。
716例接受LR治疗的PVTT HCC患者中,140例有脾肿大(SM组),576例无脾肿大(非SM组)。SM组进一步分为49例行脾切除术的患者(SPT组)和91例未接受脾切除术的患者(非SPT组)。PSM匹配了SM组中的140例患者和SPT组中的49例患者。脾肿大是RFS和OS不良的独立危险因素。非SM组患者的OS和RFS率显著优于SM组(OS:P<0.001;RFS:P<0.001),SPT组患者的OS和RFS率显著优于非SPT组(OS:P<0.001;RFS:P<0.001)。
脾肿大的PVTT HCC患者生存情况明显较差。因脾肿大行脾切除术可显著改善这些患者的长期生存。